Karakousis C P, Getaz E P, Bjornsson S, Henderson E S, Irequi M, Martinez L, Ospina J, Cavins J, Preisler H, Holyoke E, Holtermann O
Cancer Treat Rep. 1979 Nov-Dec;63(11-12):2009-10.
Twenty-nine patients with advanced malignant melanoma were randomized to receive DTIC at a dose of 200 mg/m2 iv on Days 1-5 and cis-dichlorodiammine-platinum(II) at a dose of 40 mg/m2 iv on Days 1 and 4, repeated every 4 weeks (group A), or the same drugs plus procarbazine at a dose of 75 mg/m2 orally daily on Days 1-8 and vincristine at a dose of 1.4 mg/m2 iv on Day 1 (group B). These drugs were generally well-tolerated, but five of 16 patients in group A and six of 13 patients in group B required dose modification for either hematologic or renal toxicity. There were six objective responses among 16 patients in group A including one complete regression, while there were two objective responses among 13 patients in group B.
29例晚期恶性黑色素瘤患者被随机分组，A组患者在第1 - 5天接受剂量为200 mg/m²的达卡巴嗪静脉注射，在第1天和第4天接受剂量为40 mg/m²的顺二氯二氨铂（II）静脉注射，每4周重复一次；B组患者接受相同药物治疗，外加丙卡巴肼，在第1 - 8天每天口服剂量为75 mg/m²，在第1天接受剂量为1.4 mg/m²的长春新碱静脉注射。这些药物一般耐受性良好，但A组16例患者中有5例、B组13例患者中有6例因血液学或肾毒性需要调整剂量。A组16例患者中有6例出现客观缓解，包括1例完全缓解，而B组13例患者中有2例出现客观缓解。
